All Articles

Historically, surgery, chemotherapy, and radiation have been the mainstay of most cancer therapies. Although these modalities have been successful and improved survival outcomes, cancer remains one of the most debilitating diagnoses, often with poor outcomes.

The authors describe the development of the online training, “Addressing the Need for LGBTQ-Affirming Cancer Care: A Focus on Sexual and Gender Minority Prostate Cancer Survivors.”

The decline in mortality from lung cancer has gone from 2% per year to 4% overall. Here’s how we’ve accomplished the decline.

Early locoregional therapy (with surgery and radiation) does not improve overall survival in women with newly diagnosed stage IV breast cancer and an intact primary tumor compared with systemic therapy alone, according to results of the ECOG-ACRIN E2108 randomized phase 3 trial presented at the Plenary Session of the ASCO20 Virtual Scientific Program.

A review of the use of scalp cooling in breast cancer treatment, the variables impacting success, and how the navigators can promote informed decision-making.

Navigators can meet the ever-growing needs of patients undergoing genetic testing. Here’s how.

Making art and telling stories with patients can lead to profound healing, according to Sharon Chappell, PhD, breast cancer survivor, author, and educator at Cal State Fullerton.

A targeted therapy used to treat non-Hodgkin lymphoma has demonstrated durable remissions in treatment-naive chronic lymphocytic leukemia (CLL), according to data presented at the ASCO20 Virtual Scientific Program.

Treatment with the anti–PD-1 antibody pembrolizumab significantly extended progression-free survival (PFS) in patients with classic Hodgkin lymphoma (HL) compared with standard brentuximab vedotin (BV) therapy in the phase 3 KEYNOTE-204 trial reported at the ASCO20 Virtual Scientific Program.

A single infusion of autologous cryopreserved tumor-infiltrating lymphocyte (TIL) therapy (lifileucel) induced responses in more than one-third of patients with advanced melanoma who had disease progression on multiple prior therapies, including anti–PD-1 and BRAF/MEK inhibitors, according to an update of a phase 2 global multicohort study.